INDIANAPOLISThe Genome Sequencing Center at Washington University School of Medicine increased its sequencing capacity with an agreement to acquire five additional Genome Sequencer FLX Systems from Roche Diagnostics.
With a total of eight Genome Sequencer FLX Systems, the Genome Sequencing Center will be able to support a wide variety of projects with the 454 Sequencing technology, ranging from the sequencing of new complex genomes to the diverse microbial world to the resequencing of portions of the human genome to identify genetic variations that may be associated with human diseases. This will include using the instruments for transcriptome analysis of individual tumors, an approach that the Genome Sequencing Center has pioneered as part of its ongoing studies of acute myeloid leukemia.
We have been able to complete several projects with the GS FLX, demonstrating the systems strengths, said Richard Wilson, Director of the Genome Sequencing Center at Washington University School of Medicine. We now believe that with the new improvements and the increased throughput of the instrument, we will be able to complete several projects more quickly than originally anticipated and at a substantially lower cost.
We are continuing to see the GS FLX moved into production settings due to the instruments scalability and reliability, which allows it to run continuously, said Lonnie Shoff, Senior Vice President of Applied Science for Roche Diagnostics. With more than 140 peer reviewed publications, we have a proven technology that continues to reshape the life sciences market.
In addition to the purchase agreement, the Genome Sequencing Center and Roche announced the Centers participation in the early access program for new technology advancements for the Genome Sequencer FLX system. The early access program will be featured Friday, Feb. 8 at the Advances in Genome Biology and Technology Conference in Marco Island, Florida.
|Contact: Lori McLaughlin|